Fosfomycin: use beyond urinary tract and gastrointestinal infections.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsFosfomycin: A First-Line Oral Therapy for Acute Uncomplicated CystitisBacillithiol: a key protective thiol in Staphylococcus aureusMolecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceStructural and Biochemical Insights into the Mechanism of Fosfomycin Phosphorylation by Fosfomycin Resistance Kinase FomAStructural and Chemical Aspects of Resistance to the Antibiotic Fosfomycin Conferred by FosB from Bacillus cereusStructure and Function of the Genomically Encoded Fosfomycin Resistance Enzyme, FosB, from Staphylococcus aureusTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsPenetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenolA cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis.Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coliFosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.Susceptibility of urinary tract bacteria to fosfomycinIn vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case reportPreliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Diversity of Acinetobacter baumannii in four French military hospitals, as assessed by multiple locus variable number of tandem repeats analysis'Old' antibiotics for emerging multidrug-resistant bacteriaIncreasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolatesESBLs: A Clear and Present Danger?Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methodsAntibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period.Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China.Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness costTreatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycinCefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species.Fosfomycin: Uses and potentialities in veterinary medicineFosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsAdverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study.FosfomycinMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Fosfomycin: Resurgence of an old companion.
P2860
Q21131083-D2B5B5AA-7E41-42FD-BA4B-5687723A4D72Q26745740-3FAEED58-7BF6-45A2-B1ED-953631AF3453Q26799816-C307CA79-7A5B-4328-993F-BA8AA391F629Q26853135-82D9A859-7ACF-4182-ABB5-12108E91E6E5Q27670667-67B2AD6E-1F8A-436C-BED2-2D9BDFA67F60Q27679869-C23D9153-54AD-41B7-AC40-A399A42A6A13Q27681408-12364E2B-12B7-41F8-B885-6CBE2EFA1EB3Q28082546-3C85F61D-EFF6-46CD-97DD-21BB477116FBQ28536930-8B4FE70B-A948-4483-80A7-363066EBFE21Q31811697-F37F1630-72C4-400A-A7E1-BC3B4C6E470AQ33416937-1310B75D-6EC8-4E4E-BA72-15BF973A07C2Q33472890-4E0C5EAC-ABA4-4CEB-BAE6-A6C9133A0C51Q33494283-78261A3A-1E7A-449A-B63F-C607D21DE34DQ33558996-C97FD2A7-0ECD-4242-ADD9-A196CED20707Q33564290-4442969B-CA0F-4898-9B50-C71AB4613DA0Q33593516-6C24E1AE-31F3-4A13-8087-D8D00FB3DF3DQ33911941-22CAD02F-D860-4B6D-95B8-849C7905BEE0Q34057525-4C55F140-FB35-4ECD-A23D-AC5901BEEF15Q34327857-3205439D-1CEE-4302-B948-021442A847F8Q34415986-6AABEA13-F4CE-47E6-95C9-394F09CE8009Q34565772-193C8FAA-2F89-4E7D-A40F-10E942B5B1BEQ35025362-2CBCB579-CFE5-4B4A-A601-B92CCBEB6550Q35076855-FA7FBF5D-954C-40BA-BF41-5E918CC1F7EBQ35101453-37C0587B-68CD-4CEB-BF91-9EA1FC8EF551Q35191584-E7720153-7D72-4462-99C3-4A72AA631D85Q35796552-D9173AA8-45E0-44A8-9376-5C70E4EE6957Q35867426-B5FE849F-3FA5-43A0-91ED-5851573CBB3EQ35941216-2D32A290-7553-49DA-B88C-7024C758468BQ35959558-4D2C0CC0-6DD6-4AB8-A990-C492754E95A7Q35966554-3C446591-1D10-4C26-8D43-80DBF6A69ADAQ36160749-19C6E952-CF42-40C5-A78C-FA8D503DC14FQ36171710-73E9D6C7-3240-4FC8-B6C8-6E841888AEE9Q36239060-935A36BD-6988-4706-B67A-F8C71EC95F86Q36276787-3B730307-CAC8-4A35-B54A-21FF25532EB0Q36361921-ECCDF798-9030-4258-AB1F-A628E7347FE3Q36363257-EC27F10B-780B-4B10-B256-12F9089D461BQ36449942-66FEAAF1-AB36-46C1-9CBB-086AAA313A98Q36675246-EBCBD767-83C1-4A17-8930-0D54CD66F712Q36761826-47AD20C0-B8B0-4269-9305-60EFD45E0BE6Q36803694-D3B0D497-1FA8-4DE4-91B9-9A7F37149968
P2860
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@ast
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@en
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@nl
type
label
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@ast
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@en
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@nl
prefLabel
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@ast
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@en
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@nl
P2860
P356
P1476
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
@en
P2093
George N Kokolakis
Konstantina P Giannopoulou
P2860
P304
P356
10.1086/527442
P407
P577
2008-04-01T00:00:00Z